Policy 2: Credibility, Convergence and the 2021 Global Liver Institute Action Plan - Ep 42
Send us a text Donna Cryer and Global Liver Institute Director of Policy Andrew Scott return to discuss their 2021 US NASH Action Plan, garnering support for the new COVID-19 vaccines and the importance of aligning stakeholders with Stephen, Louise and Roger. The Surfers end the year on an optimistic note by talking with sometime-surfer Donna Cryer and GLI Director of Policy Andrew Scott about GLI's ambitious 2021 US NASH Action Plan, which should be released by the time you read this. The p...
17 Dec 202048min
Policy 1: The Liver Policy Agenda Has Experienced Surprising Success in the Last Four Years - Ep 41
Send us a text Donna Cryer and Global Liver Institute Director of Policy Andrew Scott join Stephen, Louise and Roger to discuss the policy progress liver disease and NASH have made in the last four years. This is the first of two epiodes discussing Public Policy questions that affect how stakeholders view NAFLD andNASH as a disease as well as the process by which related drugs and diagnostics are evaluated. Today's episode addresses the many kinds of progress that liver policy has made in th...
10 Dec 20201h 1min
Links between NAFLD and Cardiovascular Disease - Ep 40
Send us a text Dr Ian Rowe and Prof. Dr. Jörn M. Schattenberg joins the Surfers to explore the relationship between NAFLD and CVD in light of recent work questioning the strength of links between the two This episode asks how to reconcile results from a presentation at EASL suggesting that the primary cause of death from NAFLD patients is liver disease and the low level of CVD events in the STELLAR-3 and STELLAR-4 trials with significant other data identifying CVD as the leading cause of dea...
3 Dec 202048min
COVID CHAOS: The 2nd Wave - Ep 39
Send us a text Guest Ian Rowe and Dr. Kris Kowdley join the Surfers to discuss how the 2nd COVID wave and arrival of the vaccine are likely to affect patient treatment and clinical development. In Episode 39, hepatologists Ian Rowe and Kris Kowdley, who divide their time more or less evenly between patient clinics and clinical trials, join the Surfers to discuss how the Second Wave of COVID-19 will affect patient treatment and clinical trials. This conversation turns conventional wisdom on i...
24 Nov 202052min
The Day After TLMdX 2020 Wrapping Up with The View from Across the Atlantic - Ep 38
Send us a text Prof. Vlad Ratziu, MD, and Prof. Dr. Jörn M. Schattenberg join the Surfers to wrap up our conversation about this year's AASLD meeting. Prof. Dr. Jörn M. Schattenberg erg and Prof. Vlad Ratziu, MD join the Surfers for our wrap-up episode for TLMdX 2020. Joern focuses on a diabetes poster demonstrating the path of drug efficacy over a three-year period, while Vlad focuses on the successful Phase 2 trial of the pan-PPAR lanifibranor. The group also asks why placebo r...
19 Nov 202058min
Day Four of TLMdX 2020 - Monday at the Digital Liver Meeting -- Getting Better at Diagnostics and Drugs, Not Education - Ep 37
Send us a text The Surfers spend the final day of AASLD 2020 looking at two very different sets of issues. Issue 1: challenges proving efficacy in F2 populations, particularly in terms of fibrosis. Issue 2: social burdens of poor dietary choices around the world, particularly given how developing PNAFLD (pediatric non-alcoholic fatty liver disease) can create a metabolic burden that can last a lifetime. In the end, the group remained optimistic about the explosion of knowledge around drugs an...
17 Nov 20201h 15min
Day Three of TLMdX 2020 - Sunday at The Digital Liver Meeting -- The Future Looks Bright! - Ep 36
Send us a text Reviews of Phase 2 drug trials and diagnostic strategies reveal that NASH is close to multiple breakthroughs. Naim Alkhouri and Mazen Noureddin join Louise and Roger to review highlights from Sunday at The Digital Liver Meeting. Naim, Mazen and Roger review results from drug trials that reveal that multiple drugs (monotherapies and combinations) with potent effects on liver fat reduction and fibrosis are moving through the pipeline. Louise discusses a trial that relies on non-...
16 Nov 20201h 10min
Day Two of TLMdX 2020 - Lean NASH, exciting Diagnostics and Patient-Reported Outcomes as an Endpoint - Ep 35
Send us a text Manal Abdelmalek joins the Surfers to review some of Saturday's most exciting presentations and posters from AASLD 2020, followed by a discussion of an exciting new hand-held diagnostic. Manal Abdelmalek joins the Surfers in a free-flowing discussion of Saturday's key papers and posters. Much of the talk focused on Lean NASH -- what it is some of the new diagnostic analyses and algorithms used to identify patients with or at risk of the disease. Stephen talked about the extra...
15 Nov 20201h 27min
